tedgoeseast
5 years ago
check out r#oth big names loading float under 200 mill just going current sos just made upto date news coming ,My buddy was taking to the CEO on Linkedin..read all posts on the message board ,we need whales and lots of them maybe a ,virus big play
Company is active in Colorado SOS
CEO said he is actively working on getting current on OTCmarkets..
It cost at least $10k to do that..
From my research company is making revenues in a few countries (outside the US)
expecting big things
Company has 0 notes and no history of RS
all signs are very positive and I have taken a position..
Expecting LFAP, VYST run here, if not bigger!!
Corono Virus products would send her super Nova!!
I'm load on the bid at current levels
houtheman
15 years ago
IAGX coverage starts $1.25 price target
http://finance.yahoo.com/news/RedChip-Visibility-Initiates-pz-4180667132.html?x=0&.v=1
ORLANDO, Fla., Sept. 30, 2009 (GLOBE NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., has initiated coverage on Imagenetix Inc. (OTCBB:IAGX - News), an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis.
Related Quotes
Symbol Price Change
IAGX.OB 0.81 0.00
Chart for IMAGENETIX INC
{"s" : "iagx.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Harry Russell, MBA, RedChip Research Analyst, reported:
"Imagenetix is a neutraceutical company with a suite of proprietary, scientifically tested, validated, and naturally based products. The Company's main focus is on anti-inflammation; and, its lead product, Celadrin(R), is being strategically positioned with mass marketers. With the existing traction that the Company has with Celadrin, there should be substantial operating leverage going forward and a more seamless positioning of the Company's other products.
The Company is well-positioned in very large markets; and, although these markets are competitive, most of the challenges that are presented to new entrants are behind them. Finally, because of their large distribution capabilities, revenue growth can be generated in a very short period of time.
Because the Company has its most challenging days behind it and, further, because of the validation they have earned with large vendor organizations, we feel now is a critical time for investment. For this reason, we are initiating coverage of IAGX with a 'Speculative Buy' recommendation and a 12-month price target of $1.25."